Synthesis and characterization of two pet radioligands for the metabotropic glutamate 1 (mGlu1) receptor

Synapse

Volumn 66, Issue 12, 2012, Pages 1002-1014

  Huang, Yiyun ^a   Narendran, Rajesh ^a   Bischoff, Francois ^b   Guo, Ningning ^a   Bae, Sung A ^a   Hwang, Dah Ren ^a   Lesage, Anne S ^b   Laruelle, Marc ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Metabotropic glutamate receptor; Radioligand; Synthesis

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CARBON 11; FLUORINE 18; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BINDING AFFINITY; CEREBELLUM; CORPUS STRIATUM; DRUG BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MEDULLA OBLONGATA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AMINO ACIDS; ANIMALS; BRAIN; CARBON RADIOISOTOPES; CHO CELLS; CRICETINAE; CRICETULUS; EXCITATORY AMINO ACID ANTAGONISTS; FLUORINE RADIOISOTOPES; LIGANDS; MALE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; QUINOLINES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; TISSUE DISTRIBUTION; XANTHENES;

EID: 84867633995     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21606     Document Type: Article

References (41)

1. 123I]iomazenil: Kinetic and equilibrium paradigms. J Nucl Med 35: 228-238.
2. 11C]NNC 756. Synapse 32: 93-109.
3. Bordi F, Ugolini A. 1999. Group I metabotropic glutamate receptors: Implications for brain diseases. Prog Neurobiol 59: 55-79.
4. Conn PJ. 2003. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 1003: 12-21.
5. Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
6. 3H]-Methoxy-PEPy: Potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13: 351-354.
7. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, Rao S, Washburn M, Varney MA. 2003b. 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46: 204-206.
8. Elfving B, Bjornholm B, Ebert B, Knudsen GM. 2001. Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse 41: 203-211.
9. 18F]fluoro-3-pyridyl)-5-methyl-1H-1, 2, 3-triazol-4-yl]quinoline for positron emission tomography imaging of the metabotropic glutamate receptor type 1 in brain. Bioorg Med Chem 19: 102-110.
10. 18F]fluoro-3-pyridyl)-4-(2-isopropyl-1-oxo-isoindoline-5-yl)-5-methyl-1H-1, 2, 3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains. J Neurochem 121: 115-124.
11. Fujinaga M, Yamasaki T, Yui J, Hatori A, Xie L, Kawamura K, Asagawa C, Kumata K, Yoshida Y, Ogawa M, Nengaki N, Fukumura T, Zhang MR. 2012b. Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain. J Med Chem 55: 2342-2352.
12. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 83: 1014-1019.
13. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 12: 407-409.
14. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R. 1999. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38: 1493-1503.
15. 18F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse 65: 125-135.
16. 11C]methyl-6-quinolinyl)(cis-4-methoxycyclohexyl)methanone. J Med Chem 48: 5096-5099.
17. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD. 1998. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37: 1-12.
18. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14: 453-465.
19. 123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263: 39-51.
20. 3H]R214127: A novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63: 1082-1093.
21. 3H]R214127. Neuropharmacology 46: 609-619.
22. Lavreysen H, Wouters R, Bischoff F, Nobrega Pereira S, Langlois X, Blokland S, Somers M, Dillen L, Lesage AS. 2004b. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47: 961-972.
23. Mabire D, Coupa S, Adelinet C, Poncelet A, Simonnet Y, Venet M, Wouters R, Lesage AS, Van Beijsterveldt L, Bischoff F. 2005. Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J Med Chem 48: 2134-2153.
24. Moghaddam B. 2004. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174: 39-44.
25. Mu L, Schubiger PA, Ametamey SM. 2010. Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5). Curr Top Med Chem 10: 1558-1568.
26. 3H]quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem 75: 2590-2601.
27. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wislowska A, Plaznik A, Bespalov AY, Danysz W. 2005. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514: 25-34.
28. Pin JP, Acher F. 2002. The metabotropic glutamate receptors: Structure, activation mechanism and pharmacology. Curr Drug Target CNS Neurol Disord 1: 297-317.
29. 11C]MMTP: A potential PET ligand for mGluR1 receptors. Bioorg Med Chem Lett 20: 3499-3501.
30. Rowland M, Tozer TN. 1989. Clinical pharmacokinetics. Philadelphia, PA: Lea & Febiger.
31. Satoh A, Nagatomi Y, Hirata Y, Ito S, Suzuki G, Kimura T, Maehara S, Hikichi H, Satow A, Hata M, Ohta H, Kawamoto H. 2009. Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1, 3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist. Bioorg Med Chem Lett 19: 5464-5468.
32. 2 receptors in nonhuman primates. Psychopharmacology (Berl) 175: 274-286.
33. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. 2003. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: Behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14: 257-277.
34. Spooren WP, Gasparini F, Salt TE, Kuhn R. 2001. Novel allosteric antagonists shed light on mglu receptors and CNS disorders. Trends Pharmacol Sci 22: 331-337.
35. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J, Megens A, Lesage AS. 2005. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 179: 198-206.
36. Wilson AA, Jin L, Garcia A, DaSilva JN, Houle S. 2001. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot 54: 203-208.
37. Woods RP, Mazziotta JC, Cherry SR. 1993. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17: 536-546.
38. 18F]FITM. Eur J Nucl Med Mol Imaging 39: 632-641.
39. 18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1, 3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett 21: 2998-3001.
40. 11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1. Nucl Med Biol 37: 615-624.
41. Yu M. 2007. Recent developments of the PET imaging agents for metabotropic glutamate receptor subtype 5. Curr Top Med Chem 7: 1800-1805.